These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9617324)

  • 1. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
    Aoyama H; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
    Nomura Y; Nakajima M; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group].
    Nomura Y; Abe O; Enomoto K; Fujiwara K; Tominaga T; Hayashi K; Uchino J; Takahashi M; Hayasaka A; Asaishi K; Okazaki M; Abe R; Kimishima I; Kajiwara T; Haga S; Shimizu T; Miyazaki I; Noguchi M; Yoshida M; Miura S; Taguchi T; Oota J; Sakai K; Kinoshita H; Tashiro H
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):553-61. PubMed ID: 9530362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
    Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial].
    Aoyama H; Asaishi K; Abe R; Kajiwara T; Enomoto K; Yoshida M; Ohasi Y; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):477-84. PubMed ID: 8129388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
    Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].
    Morimoto K; Abe O; Kinoshita H
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1565-73. PubMed ID: 9725050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I study of FK 435].
    Abe O; Enomoto K; Fujiwara K; Izuo M; Iino Y; Tominaga T; Hayashi K; Takatani O; Kugai N; Yoshida M
    Gan No Rinsho; 1990 Jul; 36(8):903-13. PubMed ID: 2195179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II study of THP (2''R)-4'-0-tetrahydropyranyladriamycin) in breast cancer].
    Abe O; Enomoto K; Tominaga T; Kasai Y; Soejima S; Kasai M; Izuo M; Yoshida M; Kubo K; Terasawa T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):578-85. PubMed ID: 3954379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
    Furue H; Machida T; Masaoka T; Ikeda S
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
    Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
    Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
    Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].
    Mitsuyama S; Nomura Y; Ohno S; Miyauchi M; Yamamoto N; Kimura T; Saku M; Miura S; Yoshikawa N; Tsujinaka T; Koh J; Ishida T; Abe O; Ohashi Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2071-7. PubMed ID: 16352931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
    Tominaga T; Suzuki T
    Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.